Would it surprise you to know that we bring innovation to the field of generic medicine? Or that our research and development group includes more than 2,600 scientists who innovate worldwide every day?
It’s true. And it’s why we've challenged ourselves to reach higher and go further for more than 50 years.
Today we design bioequivalent versions of brand name medicines, many of which are difficult-to-manufacture and difficult-to-formulate. We strive to create enhanced versions of medicines to differentiate our products from the pack. And we pursue innovations in oral solid dose medicines, transdermals, injectables, creams, ointments, antiretrovirals and nearly a dozen other critical areas.
Why? Because we believe every disease can have a treatment. We believe every epidemic should come to an end. Medical conditions great and small should be manageable.
Anaphylaxis, a life-threatening allergic reaction, is a significant public health problem. When anaphylaxis occurs, every minute matters and immediate access to adrenaline and emergency medical care is crucial. We advocate for increased anaphylaxis awareness, preparedness and access to treatment,
because even one anaphylactic episode without access to adrenaline is one too many.
These medicines treat HIV/AIDS. Often, treatment regimens require a patient to take three or more medicines and may include an ARV medicine that breaks down if not refrigerated. Many places hardest hit by the epidemic are in warm climates—Africa and India, for instance—where refrigeration can be scarce. For such regions, Mylan was able to make a heat-stable version of an ARV medicine that doesn’t require refrigeration.
Our commitment to cardiovascular medicine beats strongly. Using our transdermal technology, we have formulated adhesive patches that deliver medicine through the skin.
We’re developing asthma and chronic obstructive pulmonary disease (COPD) treatments that use a dry-powder drug-delivery platform technology. Find out more about our other brand name respiratory products.
While we manufacture products in many formats, from tablets and capsules to injectables and transdermals, we also produce creams and ointments for dermatology. Our commitment to these medicines gained strength during the 1990s, when we acquired Bertek Pharmaceuticals. Today, we have several products in clinical trials awaiting approval as well as many creams, ointments, sprays and dressings.
Central Nervous System
Mylan products are the second-most dispensed in the neurological category. These are difficult-to-manufacture and difficult-to-formulate products that treat serious diseases. Our innovation in this category has made us a leader in this area.